Posts

Psychedelic Business Spotlight – June 24

This Week in Psychedelic Stocks: Compass Pathways Wins Patent Battle, MindMed Patents Candy Flipping, and More!

, ,
This week in psychedelic stock news, there are big patent developments for Compass, MindMed and Numinus.

Psychedelic Business Spotlight – June 10

,
This week in psychedelic business news: Cybin acquires a Phase 1 DMT trial from Entheon; Numinus completed the acquisition of Novamind, MindMed's stock is removed from an index; and...
Does MDMA Reduce Fear?

Does MDMA Reduce Fear? New Study Has Implications for PTSD Treatment

,
Using a measurement tool called the SCR, researchers found that combining MDMA with fear extinction learning and recall therapy significantly reduced the fear felt by study participants, as compared...
MindMed, atai Life Sciences, Compass Pathways: A Psychedelic Stock AnalysisShutterstock

Comparing MindMed, Atai Life Sciences, Compass Pathways: A Psychedelic Stock Analysis

, ,
Our resident psychedelic investor explains a handful of important metrics to study when analyzing and comparing psychedelic stocks.

Psychedelic Business Spotlight – May 13

,
This week in psychedelic business news: Beckley Retreats set launch; another shark swims into the psychedelics industry; and MindMed shares promising LSD study results.
MindMed's Phase 2 LSD Trial Treating Anxiety Was a SuccessShutterstock

MindMed’s Phase 2 LSD Trial Treating Anxiety Was a Success

, ,
Researchers at PSYCH Symposium reveal promising results from double-blind, placebo-controlled study with 46 patients.
Why Wednesday Will Be Biggest Day for Psychedelic Investors of 2022Shutterstock

Why Wednesday Will Be Biggest Day of 2022 for Psychedelic Investors

,
Psychedelic investors are about to see pivotal data presented on flagship programs by the titans of the psychedelics industry.
Kevin O’Leary Thinks 3 Biggest Psychedelic Companies Will Merge, But Should They?Shutterstock

Kevin O’Leary Predicts These 3 Psychedelic Companies Will Merge, But Should They?

,
Our resident Psychedelic Investor James Hallifax wonders if the "Shark Tank" star's prediction makes financial sense.

Why Investors Should Care About MindMed’s LSD Trial for Anxiety

MindMed will present preliminary results from a Phase 2a study treating Generalized Anxiety Disorder with LSD therapy next month.
5 Most Important Psychedelic Clinical Trials of 2022Shutterstock

5 Most Important Psychedelic Clinical Trials in 2022

Here's why we think MAPS’ second Phase 3 MDMA trial is the most important psychedelic study of 2022, and 4 more that may have huge impacts.